Comparing Sandoz Group (OTCMKTS:SDZNY) & CERo Therapeutics (NASDAQ:CERO)

CERo Therapeutics (NASDAQ:CERO) and Sandoz Group (OTCMKTS:SDZNY) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation.

Volatility & Risk

CERo Therapeutics has a beta of 0.27, meaning that its stock price is 73% less volatile than the S&P 500. Comparatively, Sandoz Group has a beta of 0.52, meaning that its stock price is 48% less volatile than the S&P 500.

Institutional & Insider Ownership

29.6% of CERo Therapeutics shares are held by institutional investors. Comparatively, 0.1% of Sandoz Group shares are held by institutional investors. 0.4% of CERo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for CERo Therapeutics and Sandoz Group, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CERo Therapeutics	1	3	0	0	1.75
Sandoz Group	0	1	0	1	3.00

CERo Therapeutics presently has a consensus target price of $45.00, indicating a potential upside of 107,042.86%. Given CERo Therapeutics’ higher possible upside, equities research analysts clearly believe CERo Therapeutics is more favorable than Sandoz Group.

Profitability

This table compares CERo Therapeutics and Sandoz Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CERo Therapeutics	N/A	N/A	-209.40%
Sandoz Group	N/A	N/A	N/A

Earnings and Valuation

This table compares CERo Therapeutics and Sandoz Group”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CERo Therapeutics	N/A	N/A	-$8.30 million	($102.61)	0.00
Sandoz Group	$10.36 billion	3.33	$1.00 million	N/A	N/A

Sandoz Group has higher revenue and earnings than CERo Therapeutics.

Summary

Sandoz Group beats CERo Therapeutics on 6 of the 9 factors compared between the two stocks.

About CERo Therapeutics

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.

About Sandoz Group

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland.